- Home
- PSF vs ABEO Comparison
PSF vs ABEO Comparison
Compare PSF & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | ABEO |
|---|---|---|
| Founded | 2010 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PSF | ABEO |
|---|---|---|
| Price | $20.42 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 29.2K | ★ 952.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.86 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $17.93 | $3.93 |
| 52 Week High | $21.20 | $7.54 |
Technical Indicators
Market Signals| Indicator | PSF | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 47.69 |
| Support Level | $20.33 | $4.87 |
| Resistance Level | $20.57 | $5.60 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.79 | 28.46 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.